315 related articles for article (PubMed ID: 31879125)
1. Current and future cholera vaccines.
Shaikh H; Lynch J; Kim J; Excler JL
Vaccine; 2020 Feb; 38 Suppl 1():A118-A126. PubMed ID: 31879125
[TBL] [Abstract][Full Text] [Related]
2. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
[TBL] [Abstract][Full Text] [Related]
3. Improving immunization approaches to cholera.
Saha A; Rosewell A; Hayen A; MacIntyre CR; Qadri F
Expert Rev Vaccines; 2017 Mar; 16(3):235-248. PubMed ID: 27805467
[TBL] [Abstract][Full Text] [Related]
4. Oral cholera vaccines and their impact on the global burden of disease.
Wierzba TF
Hum Vaccin Immunother; 2019; 15(6):1294-1301. PubMed ID: 30183486
[TBL] [Abstract][Full Text] [Related]
5. The history of OCV in India and barriers remaining to programmatic introduction.
Mogasale V; Kanungo S; Pati S; Lynch J; Dutta S
Vaccine; 2020 Feb; 38 Suppl 1():A41-A45. PubMed ID: 31982258
[TBL] [Abstract][Full Text] [Related]
6. Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach.
Sundaram N; Schaetti C; Merten S; Schindler C; Ali SM; Nyambedha EO; Lapika B; Chaignat CL; Hutubessy R; Weiss MG
BMC Public Health; 2016 Jan; 16():36. PubMed ID: 26762151
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and acceptability of oral cholera vaccine mass vaccination campaign in response to an outbreak and floods in Malawi.
Msyamboza KP; M'bang'ombe M; Hausi H; Chijuwa A; Nkukumila V; Kubwalo HW; Desai S; Pezzoli L; Legros D
Pan Afr Med J; 2016; 23():203. PubMed ID: 27347292
[TBL] [Abstract][Full Text] [Related]
8. Global oral cholera vaccine use, 2013-2018.
Pezzoli L;
Vaccine; 2020 Feb; 38 Suppl 1(Suppl 1):A132-A140. PubMed ID: 31519444
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial.
Ali M; Qadri F; Kim DR; Islam MT; Im J; Ahmmed F; Khan AI; Zaman K; Marks F; Kim JH; Clemens JD
Lancet Infect Dis; 2021 Oct; 21(10):1407-1414. PubMed ID: 34146473
[TBL] [Abstract][Full Text] [Related]
10. Feasibility, coverage and cost of oral cholera vaccination conducted by icddr,b using the existing national immunization service delivery mechanism in rural setting Keraniganj, Bangladesh.
Khan AI; Khan IA; Siddique SA; Rahman A; Islam MT; Bhuiya MAI; Saha NC; Biswas PK; Saha A; Chowdhury F; Qadri F
Hum Vaccin Immunother; 2019; 15(6):1302-1309. PubMed ID: 30261152
[No Abstract] [Full Text] [Related]
11. Pre-emptive oral cholera vaccine (OCV) mass vaccination campaign in Cuamba District, Niassa Province, Mozambique: feasibility, vaccination coverage and delivery costs using CholTool.
Elias Chitio JJ; Baltazar CS; Langa JP; Baloi LD; Mboane RBJ; Manuel JA; Assane S; Omar A; Manso M; Capitine I; Van Rensburg C; Luiz N; Mogasale V; Marks F; Park SE; Beck NS
BMJ Open; 2022 Sep; 12(9):e053585. PubMed ID: 36547726
[TBL] [Abstract][Full Text] [Related]
12. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.
Desai SN; Pezzoli L; Alberti KP; Martin S; Costa A; Perea W; Legros D
Hum Vaccin Immunother; 2017 Mar; 13(3):579-587. PubMed ID: 27813703
[TBL] [Abstract][Full Text] [Related]
13. Trials of the killed oral cholera vaccine (Shanchol) in India and Bangladesh: Lessons learned and way forward.
Islam MT; Chowdhury F; Qadri F; Sur D; Ganguly NK
Vaccine; 2020 Feb; 38 Suppl 1():A127-A131. PubMed ID: 31301917
[TBL] [Abstract][Full Text] [Related]
14. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.
Kar SK; Sah B; Patnaik B; Kim YH; Kerketta AS; Shin S; Rath SB; Ali M; Mogasale V; Khuntia HK; Bhattachan A; You YA; Puri MK; Lopez AL; Maskery B; Nair GB; Clemens JD; Wierzba TF
PLoS Negl Trop Dis; 2014 Feb; 8(2):e2629. PubMed ID: 24516675
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia.
Teshome S; Desai S; Kim JH; Belay D; Mogasale V
Hum Vaccin Immunother; 2018; 14(10):2427-2433. PubMed ID: 29648523
[TBL] [Abstract][Full Text] [Related]
16. Oral cholera vaccination coverage after the first global stockpile deployment in Haiti, 2014.
Burnett EM; Francois J; Sreenivasan N; Wannemuehler K; Faye PC; Tohme RA; Delly P; Deslouches YG; Etheart MD; Dismer AM; Patel R; Date K
Vaccine; 2019 Oct; 37(43):6348-6355. PubMed ID: 31521413
[TBL] [Abstract][Full Text] [Related]
17. Oral cholera vaccine delivery strategy in India: Routine or campaign?-A scoping review.
Ray A; Sarkar K; Haldar P; Ghosh R
Vaccine; 2020 Feb; 38 Suppl 1():A184-A193. PubMed ID: 31377080
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
Murray J; McFarland DA; Waldman RJ
Bull World Health Organ; 1998; 76(4):343-52. PubMed ID: 9803585
[TBL] [Abstract][Full Text] [Related]
19. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?
Clemens J; Holmgren J
Curr Top Microbiol Immunol; 2014; 379():231-58. PubMed ID: 24402712
[TBL] [Abstract][Full Text] [Related]
20. Unmasking herd protection by an oral cholera vaccine in a cluster-randomized trial.
Ali M; Qadri F; Kim DR; Islam T; Im J; Ahmmed F; Chon Y; Islam Khan A; Zaman K; Marks F; Clemens JD
Int J Epidemiol; 2019 Aug; 48(4):1252-1261. PubMed ID: 30968110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
